When endogenous TGF-β was inhibited by a TGF-β receptor inhibitor, FGFR isoform switching and the regulation of FGFR1 and FGFR2 mRNA were not significantly altered in OSCC cells, in agreement with our previous observation in breast cancer cells[6]. This evidence concerns the gene FGFR1 and breast carcinoma.